Otolith Labs Rounds Out Executive Team with Appointment of Kevin Franck, PhD, MBA as Chief Clinical Officer [Yahoo! Finance]
Korro Bio, Inc. (KRRO)
Company Research
Source: Yahoo! Finance
WASHINGTON, May 07, 2024 BUSINESS WIRE Otolith Labs , a medical technology company developing non-invasive wearable medical devices for the treatment of vestibular disorders, appointed Kevin Franck, PhD, MBA as Chief Clinical Officer. Kevin is a leader in the inner-ear field with 25 years of experience in the development, commercialization, and clinical provision of hearing-related medical products. As a biotech and medical device executive, Kevin Franck has held numerous leadership roles in the Ear, Nose and Throat (ENT) industry, most recently as SVP, Strategic Marketing and New Product Planning at Frequency Therapeutics, Director of Audiology at Massachusetts Eye and Ear, Faculty of the Department of Otolaryngology-Head and Neck Surgery at Harvard Medical School, and Head of Marketing for Bose Hear at Bose Corporation upon acquisition of Ear Machine, a startup funded by the National Institute of Health. He also held senior roles at Cochlear Ltd. in Sydney, Australia. Dr. Franc
Show less
Read more
Impact Snapshot
Event Time:
KRRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRRO alerts
High impacting Korro Bio, Inc. news events
Weekly update
A roundup of the hottest topics
KRRO
News
- Korro Bio, Inc. (NASDAQ: KRRO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $95.00 price target on the stock.MarketBeat
- Korro Bio, Inc. (NASDAQ: KRRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic CandidatesGlobeNewswire
- Korro to Participate in Upcoming Investor ConferencesGlobeNewswire
- Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of DirectorsGlobeNewswire
KRRO
Earnings
- 8/13/24 - Miss
KRRO
Sec Filings
- 9/16/24 - Form 424B3
- 9/16/24 - Form 424B3
- 9/16/24 - Form 8-K
- KRRO's page on the SEC website